Home Cart Sign in  
Chemical Structure| 1238697-26-1 Chemical Structure| 1238697-26-1

Structure of Balipodect
CAS No.: 1238697-26-1

Chemical Structure| 1238697-26-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TAK-063 is a highly potent, selective and orally active PDE10A inhibitor with IC50 of 0.30 nM, displaying > 15000-fold selectivity over other PDEs.

Synonyms: TAK-063

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Balipodect

CAS No. :1238697-26-1
Formula : C23H17FN6O2
M.W : 428.42
SMILES Code : FC1=CC(N2N=CC=C2)=CC=C1N3N=C(C4=CC=NN4C5=CC=CC=C5)C(C(OC)=C3)=O
Synonyms :
TAK-063
MDL No. :MFCD28385852
InChI Key :KVHRYLNQDWXAGI-UHFFFAOYSA-N
Pubchem ID :46848915

Safety of Balipodect

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • PDE10A

    PDE10A, IC50:0.3 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
human sperm 0.01, 0.1, 1 μM 4 h Significantly enhanced total, progressive, and hyperactive motility, increased protein phosphorylation levels without inducing acrosomal exocytosis or DNA fragmentation Reproduction. 2025 Mar 3;169(4):e240448
human recombinant PDE10A2 0.30 nM Evaluate the inhibitory activity and selectivity of TAK-063 for PDE10A2 PLoS One. 2015 Mar 27;10(3):e0122197
Medium spiny neurons (MSNs) in rat corticostriatal brain slices 1 μmol/L at least 15 min To evaluate the effects of TAK-063 on NMDA receptor-mediated synaptic responses, results showed that TAK-063 significantly increased peak amplitudes and decay times of NMDAR EPSP in both direct and indirect pathway MSNs. Pharmacol Res Perspect. 2018 Feb;6(1):e00372

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Fmr1 KO mouse model Oral 0.5 mg/kg and 5 mg/kg Once daily for 14 days To test the effects of TAK-063 on EEG biomarkers in Fmr1 KO mice, results showed TAK-063 significantly improved phase coherence to auditory stimuli Neurotherapeutics. 2021 Apr;18(2):1175-1187
Rats PDE10A occupancy study Oral 0, 0.03, 0.1, 0.3, 1, 3, and 10 mg/kg Single dose To evaluate PDE10A occupancy by TAK-063 Int J Neuropsychopharmacol. 2020 Nov 26;23(8):524-532
Mice Striatal or cortical stroke model Intraperitoneal injection 0.3 mg/kg, 3.0 mg/kg, and 10 mg/kg Once daily for 9 weeks TAK-063 improved motor recovery after striatal stroke in a dose-related manner, but not in cortical stroke. Recovery of motor function correlated with increases in striatal brain-derived neurotrophic factor. TAK-063 treatment also increased motor system axonal connections. Transl Stroke Res. 2021 Apr;12(2):303-315
Rats Sprague-Dawley rats Oral 1.5 mg/kg Single dose, evaluated after 6 hours Validate the selective binding of TAK-063 to PDE10A in vivo PLoS One. 2015 Mar 27;10(3):e0122197
Rats METH- or MK-801-induced hyperactivity model Oral 0.1 mg/kg Single administration, activity counts assessed over 2 hours To evaluate the effects of combined treatment with TAK-063 and antipsychotics on hyperactivity models, results showed that the combination significantly suppressed METH- or MK-801-induced hyperactivity. Pharmacol Res Perspect. 2018 Feb;6(1):e00372

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.33mL

0.47mL

0.23mL

11.67mL

2.33mL

1.17mL

23.34mL

4.67mL

2.33mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories